Century Therapeutics Net Income

Century Therapeutics (IPSC) currently reports a net income of $-110M as of March 2026. That compares with $-22M in the prior-year period — down 391.1% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Century Therapeutics's net income history and peer comparisons.

Century Therapeutics's net income decreased from $-22M to $-110M — a 391.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Century Therapeutics's net income of $-110M is lower than the Healthcare sector average of $16B. That is roughly 100.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Century Therapeutics reported $-110M in net income as of March 2026. That compares with $-22M in the prior-year period — down 391.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-110M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Century Therapeutics, and consider following IPSC for alerts when major investors trade the stock.